Form 4: ACADIA Pharmaceuticals Director Sells Over 14,000 Shares of Common Stock

Laura Brege, a Director at ACADIA Pharmaceuticals Inc., reported the sale of 14,446 shares of the company's common stock at a weighted average price of $21.78 per share.

Summary

• Laura Brege, a Director of ACADIA PHARMACEUTICALS INC. (ACAD), sold 14,446 shares of common stock.
• The transaction occurred on June 4, 2025.
• The shares were sold at a weighted average price of $21.78, with individual transactions ranging from $21.77 to $21.81.
• Following this sale, Ms. Brege directly owns 15,095 shares of ACADIA PHARMACEUTICALS INC. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be viewed negatively, this is a routine disclosure of a transaction that is not exceptionally large relative to the company's market capitalization or the director's remaining holdings, and it could be part of a pre-planned trading arrangement (Rule 10b5-1(c)).

Negatives

• A director's sale of shares, while potentially for personal financial planning, can sometimes be perceived by investors as a lack of confidence in the company's near-term prospects.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends. It reflects an individual director's activity rather than a company-wide strategic move.

Related Party Transactions

• The reported transaction is an insider sale by a director, which is a type of related party transaction.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a minor negative signal, though the impact is likely minimal given the transaction size relative to the company's overall valuation.

Key Dates

Keywords

ACADIA Pharmaceuticals, ACAD, Insider Trading, Form 4, Director Share Sale, Stock Transaction, Laura Brege